Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel
Open Access
- 1 December 2006
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 42 (18), 3267-3273
- https://doi.org/10.1016/j.ejca.2006.07.003
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?European Journal Of Cancer, 2005
- Clinical trials in metastatic prostate cancer – Has there been real progress in the past decade?European Journal Of Cancer, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Molecular markers and determinants of prostate cancer metastasisJournal of Cellular Physiology, 2001
- Current status of cytotoxic chemotherapy in hormone refractory prostate cancer.European Urology, 2001
- Recent advances in the treatment of prostate cancerAnnals Of Oncology, 1999
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Phase II trials of docetaxel (taxotere®) in advanced ovarian cancer—an updated overviewEuropean Journal Of Cancer, 1997
- Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.Journal of Clinical Oncology, 1997
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996